Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI WW FrankfurtCPhI WW Frankfurt
Not Confirmed
Not Confirmed
28-30 October, 2025
Pharma MES 2025Pharma MES 2025
Not Confirmed
Not Confirmed
10-11 October, 2025
Not Confirmed
Not Confirmed
11-14 October, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Not Confirmed
28-30 October, 2025
Pharma MES 2025Pharma MES 2025
Industry Trade Show
Not Confirmed
10-11 October, 2025
Industry Trade Show
Not Confirmed
11-14 October, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/we-bridge-the-gap-between-chemistry-and-performance-to-deliver-precise-optimized-micronization-for-complex-apis
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/global-api-micronization-market-set-to-surge-49-by-2030-led-by-specialized-industry-pioneers
08 Oct 2025
// INDPHARMAPOST
https://www.indianpharmapost.com/news/redhill-biopharma-inks-18-million-middle-east-licensing-deal-for-talicia-17961
29 Sep 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/redhill-wins-new-york-supreme-court-appeal-upholding-10-million-summary-judgment-against-kukbo-302569391.html
20 Aug 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/redhill-biopharma-awarded-1-8-million-in-legal-costs-and-expenses-by-new-york-supreme-court-in-addition-to-its-prior-8-25-million-summary-judgment-win-302534579.html
18 Aug 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/redhill-received-talicia-licensing-payments-totaling-1-1-million-302532195.html
03 Jul 2025
// INDPHARMAPOST
https://www.indianpharmapost.com/diagnostic-center/redhill-biopharma-initiates-expanded-phase-2-study-combining-opaganib-and-darolutamide-in-advanced-prostate-cancer-17351
01 Jul 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/redhill-biopharma-announces-recruitment-initiated-into-expanded-phase-2-opaganibdarolutamide-combination-study-in-advanced-prostate-cancer-302495709.html
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE